These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 18281495)

  • 1. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Holmes JL; Sharp SY; Hobbs S; Workman P
    Cancer Res; 2008 Feb; 68(4):1188-97. PubMed ID: 18281495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel C-terminal homologue of Aha1 co-chaperone binds to heat shock protein 90 and stimulates its ATPase activity in Entamoeba histolytica.
    Singh M; Shah V; Tatu U
    J Mol Biol; 2014 Apr; 426(8):1786-98. PubMed ID: 24486610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of the HSP90 molecular chaperone: current status.
    Sharp S; Workman P
    Adv Cancer Res; 2006; 95():323-48. PubMed ID: 16860662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells.
    Samant RS; Clarke PA; Workman P
    Proc Natl Acad Sci U S A; 2014 May; 111(18):6834-9. PubMed ID: 24760825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
    Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
    Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition.
    Enomoto A; Fukasawa T; Takamatsu N; Ito M; Morita A; Hosoi Y; Miyagawa K
    Eur J Cancer; 2013 Nov; 49(16):3547-58. PubMed ID: 23886587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.
    Krishnamoorthy GP; Guida T; Alfano L; Avilla E; Santoro M; Carlomagno F; Melillo RM
    J Biol Chem; 2013 Jun; 288(24):17481-94. PubMed ID: 23629654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.
    Rao R; Fiskus W; Yang Y; Lee P; Joshi R; Fernandez P; Mandawat A; Atadja P; Bradner JE; Bhalla K
    Blood; 2008 Sep; 112(5):1886-93. PubMed ID: 18591380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.
    Rodrigues LM; Chung YL; Al Saffar NM; Sharp SY; Jackson LE; Banerji U; Stubbs M; Leach MO; Griffiths JR; Workman P
    BMC Res Notes; 2012 May; 5():250. PubMed ID: 22621282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.
    Shintani S; Zhang T; Aslam A; Sebastian K; Yoshimura T; Hamakawa H
    Int J Oncol; 2006 Nov; 29(5):1111-7. PubMed ID: 17016641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
    Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells.
    Cervantes-Gomez F; Nimmanapalli R; Gandhi V
    J Pharmacol Exp Ther; 2011 Nov; 339(2):545-54. PubMed ID: 21821695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
    Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
    Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors.
    Smith JR; Clarke PA; de Billy E; Workman P
    Oncogene; 2009 Jan; 28(2):157-69. PubMed ID: 18931700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function.
    Li Y; Zhang T; Schwartz SJ; Sun D
    Nutr Cancer; 2011; 63(7):1151-9. PubMed ID: 21875325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P; Gastaldi T; Falini B; Rosolen A
    Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
    Liu H; Zhang T; Chen R; McConkey DJ; Ward JF; Curley SA
    J Surg Res; 2012 Jul; 176(1):147-53. PubMed ID: 22099584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.
    Powers MV; Clarke PA; Workman P
    Cancer Cell; 2008 Sep; 14(3):250-62. PubMed ID: 18772114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells.
    Liu X; Ban LL; Luo G; Li ZY; Li YF; Zhou YC; Wang XC; Jin CG; Ye JG; Ma DD; Xie Q; Huang YG
    Anticancer Drugs; 2016 Jun; 27(5):417-26. PubMed ID: 26872308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.